A phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR1-02 (5-FU-miR-15a) in patients with acute myeloid leukemia
Latest Information Update: 09 Jun 2025
At a glance
- Drugs CR1 02 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Jun 2025 New trial record